Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
20
05
2022
received:
07
02
2022
accepted:
26
06
2022
pubmed:
1
7
2022
medline:
5
11
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Paradoxical reactions (PRs) are defined as the occurrence during biologic therapy of a pathological condition that usually responds to these drugs. To estimate the incidence of PRs and identify risk factors. Multicentre study of the database for the Greater Paris University Hospitals, including biologic-naive patients receiving anti-tumour necrosis factor-α, anti-interleukin-12/23, anti-interleukin-17 or anti-α4β7-integrin agents for psoriasis, inflammatory rheumatism or inflammatory bowel disease (IBD). We used natural language processing algorithms to extract data. A cohort and a case-control study nested in the cohort with controls selected by incidence density sampling was used to identify risk factors. Most of the 9303 included patients (median age 43·0, 53·8% women) presented an IBD (3773, 40·6%) or a chronic inflammatory rheumatic disease (3708, 39·9%), and 8489 (91·3%) received anti-TNF-α agents. A total of 297 (3·2%) had a PR. The global incidence rate was 7·6 per 1000 person-years [95% confidence interval (CI) 6·8-8·5]. The likelihood of PR was associated with IBD [adjusted odds ratio (aOR) 1·9, 95% CI 1·1-3·2, P = 0·021] and a combination of at least two inflammatory diseases (aOR 6·1, 95% CI 3·6-10·6, P < 0·001) and was reduced with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and corticosteroids (aOR 0·6, 95% CI 0·4-0·8, P = 0·002; and OR 0·4, 95% CI 0·2-0·6, P = 0·002, respectively). The likelihood of PRs was associated with IBD or a combination of a least two inflammatory diseases. More studies are needed to assess the benefit of systematically adding csDMARDs for such high-risk patients. What is already known about this topic? Most published studies about paradoxical reactions concern paradoxical psoriasis in patients receiving anti-tumour necrosis factor-α agents. Few data are available for other paradoxical reactions and the most recent biologics. What does this study add? Risk of paradoxical reactions was increased with inflammatory bowel disease and a combination of at least two inflammatory diseases. Risk of paradoxical reactions was reduced with conventional synthetic disease-modifying antirheumatic drugs or corticosteroid therapy, which could be added for high-risk patients.
Sections du résumé
BACKGROUND
Paradoxical reactions (PRs) are defined as the occurrence during biologic therapy of a pathological condition that usually responds to these drugs.
OBJECTIVES
To estimate the incidence of PRs and identify risk factors.
METHODS
Multicentre study of the database for the Greater Paris University Hospitals, including biologic-naive patients receiving anti-tumour necrosis factor-α, anti-interleukin-12/23, anti-interleukin-17 or anti-α4β7-integrin agents for psoriasis, inflammatory rheumatism or inflammatory bowel disease (IBD). We used natural language processing algorithms to extract data. A cohort and a case-control study nested in the cohort with controls selected by incidence density sampling was used to identify risk factors.
RESULTS
Most of the 9303 included patients (median age 43·0, 53·8% women) presented an IBD (3773, 40·6%) or a chronic inflammatory rheumatic disease (3708, 39·9%), and 8489 (91·3%) received anti-TNF-α agents. A total of 297 (3·2%) had a PR. The global incidence rate was 7·6 per 1000 person-years [95% confidence interval (CI) 6·8-8·5]. The likelihood of PR was associated with IBD [adjusted odds ratio (aOR) 1·9, 95% CI 1·1-3·2, P = 0·021] and a combination of at least two inflammatory diseases (aOR 6·1, 95% CI 3·6-10·6, P < 0·001) and was reduced with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and corticosteroids (aOR 0·6, 95% CI 0·4-0·8, P = 0·002; and OR 0·4, 95% CI 0·2-0·6, P = 0·002, respectively).
CONCLUSIONS
The likelihood of PRs was associated with IBD or a combination of a least two inflammatory diseases. More studies are needed to assess the benefit of systematically adding csDMARDs for such high-risk patients. What is already known about this topic? Most published studies about paradoxical reactions concern paradoxical psoriasis in patients receiving anti-tumour necrosis factor-α agents. Few data are available for other paradoxical reactions and the most recent biologics. What does this study add? Risk of paradoxical reactions was increased with inflammatory bowel disease and a combination of at least two inflammatory diseases. Risk of paradoxical reactions was reduced with conventional synthetic disease-modifying antirheumatic drugs or corticosteroid therapy, which could be added for high-risk patients.
Substances chimiques
Antirheumatic Agents
0
Tumor Necrosis Factor Inhibitors
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
676-683Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 British Association of Dermatologists.
Références
Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340:1398-405.
Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004; 3:439-40.
Dalkilic E, Bulbul Baskan E et al. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod Rheumatol 2012; 22:738-42.
Pugliese D, Guidi L, Ferraro PM et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015; 42:880-8.
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34:1318-27.
Guerra I, Pérez-Jeldres T, Iborra M et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2016; 22:894-901.
Ya J, Hu JZ, Nowacki AS et al. Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: a case-control study. J Am Acad Dermatol 2020; 83:1599-605.
Bae JM, Kwon HS, Kim GM et al. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study. J Allergy Clin Immunol 2018; 142:1001-3.
Seneschal J, Lepreux S, Milpied B et al. Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? Arch Dermatol 2007; 143:1593-5.
Conrad C, Di Domizio J, Mylonas A et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018; 9:25.
Stoffel E, Maier H, Riedl E et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol 2018; 178:1151-62.
Seneschal J, Milpied B, Vergier B et al. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol 2009; 161:1081-8.
Korzenik J, Larsen MD, Nielsen J et al. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50:289-94.
Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL et al. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. Br J Dermatol 2017; 176:797-9.
Thiebault H, Boyard-Lasselin P, Guignant C et al. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. Eur J Gastroenterol Hepatol 2016; 28:876-81.
Faivre C, Villani AP, Aubin F et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016; 74:1153-9.
Navarro-Triviño FJ, Sanchez-Parera R, Ruiz-Villaverde R. Secukinumab-induced paradoxical hidradenitis suppurativa. Dermatol Ther 2020; 33:e13150.
Martínez-Doménech Á, García-Legaz-Martínez M, Magdaleno-Tapial J et al. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis. Dermatol Online J 2019; 25:13030/qt4624n3hj.
Munera-Campos M, Ballesca F, Richarz N et al. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol 2019; 33:e40-2.
Pirro F, Caldarola G, De Simone C et al. Multiple paradoxical reactions during ixekizumab therapy. Dermatol Ther 2019; 32:e12852.
Hlaca N, Zagar T, Kastelan M et al. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab. Clin Exp Dermatol 2021; 46:1572-3.
Benzaquen M, Flachaire B, Rouby F et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int 2018; 38:1297-9.
Fayand A, Dzierzynski N, Georgin-Lavialle S et al. The association of psychiatric comorbidities with emergency visits and hospitalisations in adult sickle-cell patients: a cohort study. Br J Haematol 2020; 189:e21-3.
Czernichow S, Beeker N, Rives-Lange C et al. Obesity doubles mortality in patients hospitalized for severe acute respiratory syndrome coronavirus 2 in Paris hospitals, France: a cohort study on 5,795 patients. Obesity (Silver Spring) 2020; 28:2282-9.
Bataille P, Amiot A, Claudepierre P et al. Letter: severe COVID-19 infection and biologic therapies - a cohort study of 7 808 patients in France. Aliment Pharmacol Ther 2020; 52:1245-8.
Chouchana L, Beeker N, Garcelon N et al. Association of antihypertensive agents with the risk of in-hospital death in patients with Covid-19. Cardiovasc Drugs Ther 2022; 36:483-8.
Brat GA, Weber GM, Gehlenborg N et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. NPJ Digit Med 2020; 3:109.
Neuraz A, Lerner I, Digan W et al. Natural language processing for rapid response to emergent diseases: case study of calcium channel blockers and hypertension in the COVID-19 pandemic. J Med Internet Res 2020; 22:e20773.
Hamon T, Grabar N. Linguistic approach for identification of medication names and related information in clinical narratives. J Am Med Inform Assoc 2010; 17:549-54.
Heidelberger V, Ingen-Housz-Oro S, Marquet A et al. Efficacy and tolerance of anti-tumor necrosis factor α agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol 2017; 153:681-5.
Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum 2017; 47:288-94.
Melani AS, Bigliazzi C, Cimmino FA et al. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther 2021; 7:325-44.
Fouache D, Goëb V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009; 48:761-4.
Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61:e59.
Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68:209-15.
Coutzac C, Chapuis J, Poullenot F et al. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study. J Crohns Colitis 2015; 9:982-7.
Glintborg B, Ostergaard M, Krogh NS et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69:2002-8.
Nissen MJ, Ciurea A, Bernhard J et al. The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol 2016; 68:2141-50.
Fagerli KM, Lie E, van der Heijde D et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014; 73:132-7.
Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol 2022; 86:1080-91.
Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol 2014; 10:159-69.